The Clinical and Economic Value of ClearGuard HD in the Inpatient Setting for Hemodialysis Catheter Management

This study was the first to assess inpatient use of ClearGuardTM HD antimicrobial barrier caps for the reduction of hemodialysis catheter-related central line-associated bloodstream infections (CLABSI) compared to the use of Tego™️ needlefree connectors with Curos™️ caps.

Retrospective observational data were used to evaluate the effect of ClearGuard on the CLABSI rate and standardized infection ratio (SIR) compared to the baseline rate and ratio. Financial analysis was conducted to measure return on investment.

Compared to the baseline period, data from the implementation period showed a long-term CLABSI reduction from 1.91/month/site (95% CI: [0.91-4.00]) to 0.71/month/site (95% CI: [0.33-1.53]), a 63% reduction (95% CI: [46%-74%]) in CLABSIs (P < .00005). The overall SIR was reduced by 57%, from a baseline of 0.721 to 0.310. The annual cost savings were estimated at $1.6 million.

The findings from the ClearGuard study and ongoing use across hospitals indicate a clinically significant reduction in hemodialysis catheter-related CLABSI events and associated costs.